DMI—a component of the trastuzumab–DMI conjugate used in the treatment of high-risk early stage and metastatic HER-2-positive breast cancer [92], is metabolised by CYP3A4 and to a lesser extent by CYP3A5. Here, CYP3A5 is linked to breast cancer.